Rheumatoid Arthritis Posts on Medivizor
Navigation Menu

Rheumatoid Arthritis Posts on Medivizor

What are the benefits of dietary fiber in patients with rheumatoid arthritis?

Posted by on Dec 29, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the effect of dietary fiber supplementation (DFS) in patients with rheumatoid arthritis (RA). They found that DFS may improve RA symptoms. Some background Rheumatoid arthritis (RA) is a condition caused by chronic inflammation. The immune system is overactive in RA. This causes pain and disability over time....

Read More

Is there a greater cancer or infection risk with abatacept treatment for rheumatoid arthritis?

Posted by on Dec 7, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the risk of infection and cancer with targeted disease-modifying anti-rheumatic drugs (tDMARDs). They found that the cancer risk is slightly higher with abatacept (Orencia) compared to other tDMARDs.  Some background Rheumatoid arthritis (RA) is a long-term autoimmune condition. Excessive inflammation...

Read More

Comparing the safety and effectiveness of peficitinib doses in patients with rheumatoid arthritis

Posted by on Nov 29, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the safety and effectiveness of different doses of peficitinib (Smyraf; PFC) in treating rheumatoid arthritis (RA). They found that PFC doses of 50 mg or higher were the most effective in these patients. Some background Rheumatoid arthritis (RA) is a chronic condition caused by inflammation....

Read More

Can early MRI changes predict treatment response and disease progression in rheumatoid arthritis?

Posted by on Nov 25, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if early changes in magnetic resonance imaging (MRI) can predict long-term response (LTR) to treatment in rheumatoid arthritis (RA).  They found that MRI changes after 1 month of treatment can predict LTR to tofacitinib (Xeljanz). Some background Rheumatoid arthritis (RA) is caused by painful...

Read More

Switching to an etanercept biosimilar – an investigation of the safety and efficacy profile

Posted by on Nov 10, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if switching from etanercept (Enbrel) to a biosimilar of etanercept (SDZ-ETN) is safe and effective in patients with rheumatoid arthritis (RA). They found that switching to SDZ-ETN from reference etanercept was safe and effective.  Some background Rheumatoid arthritis (RA) is a long-term...

Read More

An update on the long-term safety and effectiveness of etanercept in juvenile idiopathic arthritis

Posted by on Oct 20, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of etanercept (Enbrel) in juvenile idiopathic arthritis (JIA).  They found that etanercept is well tolerated and effective on the long-term in patients with JIA.  Some background Juvenile idiopathic arthritis (JIA) is an inflammatory condition...

Read More

Golimumab in rheumatoid arthritis – investigating the safety and efficacy of intravenous administration

Posted by on Oct 20, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated golimumab (Simponi; GLM) in patients with rheumatoid arthritis (RA) in patients over 65 compared to those under 65.  They found that intravenous (IV) GLM was effective and well tolerated in these patients. Some background Rheumatoid arthritis (RA) is caused by chronic inflammation in the joints. RA...

Read More

Is there a greater risk of serious infection with tumor necrosis factor inhibitors for rheumatoid arthritis?

Posted by on Sep 27, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the risk of serious infections with tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). They found no difference in serious infection risk with TNFi treatment compared to triple therapy. Some background Rheumatoid arthritis (RA) is a chronic disease. It is caused by excessive...

Read More

Is upadacitinib more effective than adalimumab in patients with rheumatoid arthritis treated with methotrexate?

Posted by on Sep 20, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated upadacitinib (Rinvoq) versus adalimumab (Humira) as add-on to methotrexate in patients with rheumatoid arthritis (RA). They found that upadacitinib was more effective in improving RA symptoms compared to adalimumab. Some background Rheumatoid arthritis (RA) is an auto-immune...

Read More

Upadacitinib improves clinical outcomes of patients with rheumatoid arthritis

Posted by on Sep 10, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the safety and effectiveness of upadacitinib (Rinvoq) in patients with rheumatoid arthritis (RA) who progressed after methotrexate (Otrexup). Researchers suggested that upadacitinib improved clinical and functional outcomes in these patients. Some background RA is an autoimmune disorder which occurs when the...

Read More